翰森制药(03692.HK)靶向抗体药物偶联物获FDA突破性疗法认定

阿斯达克财经08-21

翰森制药(03692.HK) 公布，GSK就GSK5764227(亦称HS-20093)获美国食品药品监督管理局“FDA”突破性疗法认定，此B7-H3靶向抗体药物偶联物正在评估用于含铂化疗期间或之后进展的广泛期小细胞肺癌患者治疗。HS-20093是一种新型B7-H3靶向抗体药物偶联物。

2023年12月，集团向GlaxoSmithKline授予全球独占许可以开发、生产及商业化HS-20093。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-20 16:25。)

AASTOCKS新闻

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2461567884?lang=zh_CN&edition=full","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","is_english":false,"pubTime":"2024-08-21 00:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2461567884","market":"sh","top_or_hot":-1,"title":"翰森制药(03692.HK)靶向抗体药物偶联物获FDA突破性疗法认定","media":"阿斯达克财经","content":"<html><body><div> <span> <p><a href=\"https://laohu8.com/S/03692\">翰森制药</a>(03692.HK)<span> </span>公布，GSK就GSK5764227(亦称HS-20093)获美国食品药品监督管理局“FDA”突破性疗法认定，此B7-H3靶向抗体药物偶联物正在评估用于含铂化疗期间或之后进展的广泛期小细胞肺癌患者治疗。HS-20093是一种新型B7-H3靶向抗体药物偶联物。<br/><span></span><br/>2023年12月，集团向GlaxoSmithKline授予全球独占许可以开发、生产及商业化HS-20093。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-20 16:25。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>翰森制药(03692.HK)靶向抗体药物偶联物获FDA突破性疗法认定</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n翰森制药(03692.HK)靶向抗体药物偶联物获FDA突破性疗法认定\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯达克财经</strong><span class=\"h-time small\">2024-08-21 00:55</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><div> <span> <p><a href=\"https://laohu8.com/S/03692\">翰森制药</a>(03692.HK)<span> </span>公布，GSK就GSK5764227(亦称HS-20093)获美国食品药品监督管理局“FDA”突破性疗法认定，此B7-H3靶向抗体药物偶联物正在评估用于含铂化疗期间或之后进展的广泛期小细胞肺癌患者治疗。HS-20093是一种新型B7-H3靶向抗体药物偶联物。<br/><span></span><br/>2023年12月，集团向GlaxoSmithKline授予全球独占许可以开发、生产及商业化HS-20093。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-20 16:25。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1373335/latest-news/AAFN\">阿斯达克财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1373335/latest-news/AAFN","article_id":"2461567884","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2461567884","pubTimestamp":1724172900,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"翰森制药(03692.HK) 公布，GSK就GSK5764227(亦称HS-20093)获美国食品药品监督管理局“FDA”突破性疗法认定，此B7-H3靶向抗体药物偶联物正在评估用于含铂化疗期间或之后进展的广泛期小细胞肺癌患者治疗。HS-20093是一种新型B7-H3靶向抗体药物偶联物。2023年12月，集团向GlaxoSmithKline授予全球独占许可以开发、生产及商业化HS-20093。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-20 16:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"03692":"翰森制药","BK1191":"制药","BK1589":"北水核心资产","BK1583":"高瓴概念"},"translate_title":"Hansoh Pharmaceutical (03692. HK) Targeted Antibody Drug Conjugate Obtained FDA Breakthrough Therapy Designation","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"翰森制药(03692.HK) 公布，GSK就GSK5764227(亦称HS-20093)获美国食品药品监督管理局“FDA”突破性疗法认定，此B7-H3靶向抗体药物偶联物正在评估用于含铂化疗期间或之后进展的广泛期小细胞肺癌患者治疗。HS-20093是一种新型B7-H3靶向抗体药物偶联物。2023年12月，集团向GlaxoSmithKline授予全球独占许可以开发、生产及商业化HS-20093。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-20 16:25。)AASTOCKS新闻","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2461567884"}